The DOI matches its Crossref record.
The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2: A Review
Open accessAbstract
Recent increases in knowledge of cellular immunology, combined with developments in biotechnology, have provided new opportunities for the development of immunotherapies for the treatment of cancer in humans. One approach to therapy is that of adoptive immunotherapy, that is, the transfer to the tumor bearing host of lymphoid cells with antitumor reactivity that can mediate antitumor responses. Several lymphocyte subpopulations have now been identified that may be suitable for use in adoptive immunotherapy. Resting lymphocytes incubated in interleukin-2 (IL-2) give rise to lymphokine activated killer (LAK) cells that can lyse malignant cells, but not normal cells. Clinical studies in patients with advanced cancer have revealed that treatment with high dose IL-2 alone or in combination with LAK cells can mediate the complete or partial regression of cancer in selected patients. Other approaches are currently undergoing investigation, including the adoptive transfer of tumor infiltrating lymphocytes, which, in animal models, have antitumor reactivity 50-100 times more potent than do LAK cells. Other new approaches to immunotherapy include the use of combination of lymphokines, such as the use of tumor necrosis factor or alpha interferon in conjunction with IL-2. The availability of recombinant lymphokines that provide large amounts of biologically active materials can hopefully lead to the development of effective new therapies for cancer in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Self-citationExperience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Self-citationCytokines and the Brain: Implications for Clinical Psychiatry
Kronfol, Z., & Remick, D. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.683 · Cited by 784
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
Yasumoto, K., Okamoto, S., Mukaida, N., Murakami, S., Mai, M., & Matsushima, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41701-2 · Cited by 448
Metadata
- Authors
- ROSENBERG, S. A.
- Venue
- Annals of Surgery
- Published
- 1988-08
- Volume
- 208
- Issue
- 2
- Pages
- 121-135
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2103739833
- Cited by
- 181
- References
- 0
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2: A Review. https://app.cochat.ai/papers/10.1097/00000658-198808000-00001
- The paper
- ROSENBERG, S. A. (1988). The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2: A Review. Annals of Surgery. https://doi.org/10.1097/00000658-198808000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.